Bristol-Myers Squibb Company $1.5 Billion Notes Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters on an SEC-registered public debt offering by Bristol-Myers Squibb Company of $750 million…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Davis Polk Advises Auris Medical Holding AG on Its Offering of Common Shares and Warrants to Purchase Common Shares
Davis Polk advised Auris Medical Holding AG on its $10 million public offering of 10,000,000 of its common shares and 10,000,000 warrants, each warrant entitling its holder to purchase 0.7…
Hermes Pardini R$763 Million Initial Public Offering
Davis Polk advised the joint bookrunners in connection with the initial public offering by Hermes Pardini and the selling shareholder of 40,171,429 common shares for an aggregate amount of…
Coherus BioSciences, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of Coherus BioSciences, Inc. The common stock is listed on the NASDAQ…
Davis Polk Advises McKesson Corporation on $1 Billion Notes Offering by Change Healthcare
Davis Polk advised McKesson Corporation in connection with the offering of $1 billion aggregate principal amount of notes issued by Change Healthcare Holdings, LLC and Change Healthcare…
Jounce Therapeutics, Inc. Initial Public Offering
Davis Polk advised the lead book-running manager and representative of the underwriters in connection with its $101.9 million initial public offering of common stock of Jounce Therapeutics,…
Davis Polk Advises Affimed on Its $18 Million Offering of Shares
Davis Polk advised Affimed N.V. on its $18 million public offering of 10,000,000 of its common shares. The underwriters have a 30-day option to purchase an additional 1,500,000 shares. The…
Loxo Oncology, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $138 million SEC-registered offering of 4,450,500 shares of common stock of Loxo Oncology, Inc. The common stock is…
Sucampo Pharmaceuticals, Inc. $300 Million Convertible Senior Notes Offering
Davis Polk advised the sole book-running manager and initial purchaser in connection with a Rule 144A offering by Sucampo Pharmaceuticals, Inc. of $300 million aggregate principal amount of…
Davis Polk Advises Roche on Its $250 Million Cash Tender Offer
Davis Polk advised Roche Holdings, Inc. in connection with a cash tender offer for up to $250 million aggregate principal amount of its 7.00% notes due 2039.
Headquartered in Basel,…